The mixture of an experimental BioAge Labs drug with the accredited Eli Lilly weight problems drug Zepbound has precipitated a significant setback: a security sign seen in some scientific trial contributors that led the biotech to cancel the carefully watched interim examine discontinued. The worrying sign is elevated liver enzymes, BioAge introduced after Friday's market shut. For BioAge's drug, azelaprag, […]